Loading...
XNAS
HIND
Market cap1mUSD
Jul 09, Last price  
2.23USD
1D
4.69%
1Q
1.83%
Jan 2017
-74.80%
IPO
-85.13%
Name

ReShape Lifesciences Inc

Chart & Performance

D1W1MN
XNAS:HIND chart
P/E
P/S
4.16
EPS
Div Yield, %
Shrs. gr., 5y
771.47%
Rev. gr., 5y
-50.98%
Revenues
320k
-96.01%
000000312,00000292,000786,6601,287,154606,71015,089,00011,299,00013,600,00011,240,0008,678,0008,006,000319,714
Net income
-10m
L+43.93%
-17,690,477-28,575,348-37,874,028-31,929,000-17,347,000-25,997,322-23,460,000-25,781,000-26,129,000-25,499,000-23,360,844-33,817,972-81,151,575-74,207,000-21,630,000-63,146,000-46,214,000-11,387,000-7,130,000-10,262,007
CFO
-4m
L-15.32%
-16,228,123-23,368,510-33,668,613-24,657,223-13,664,607-19,935,434-22,479,369-18,425,729-19,383,663-22,606,040-20,655,793-24,588,208-27,490,170-14,200,000-8,550,000-15,375,000-21,902,000-16,960,000-4,427,000-3,748,853

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
IPO date
Oct 06, 2016
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT